KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Rad Laboratories (BIO) EBT Margin (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed EBT Margin for 17 consecutive years, with 134.05% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin rose 27021.0% to 134.05% in Q4 2025 year-over-year; TTM through Dec 2025 was 38.54%, a 12981.0% increase, with the full-year FY2025 number at 38.54%, up 12981.0% from a year prior.
  • EBT Margin was 134.05% for Q4 2025 at Bio-Rad Laboratories, up from 66.02% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 672.32% in Q3 2021 to a low of 623.91% in Q1 2022.
  • A 5-year average of 14.15% and a median of 17.97% in 2025 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: tumbled -80239bps in 2022, then soared 63644bps in 2023.
  • Bio-Rad Laboratories' EBT Margin stood at 276.63% in 2021, then skyrocketed by 154bps to 149.44% in 2022, then tumbled by -58bps to 62.89% in 2023, then tumbled by -317bps to 136.17% in 2024, then soared by 198bps to 134.05% in 2025.
  • Per Business Quant, the three most recent readings for BIO's EBT Margin are 134.05% (Q4 2025), 66.02% (Q3 2025), and 63.54% (Q2 2025).